Amgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.
Follow AMGN
Amgen Inc. (AMGN) EPS (diluted)
Amgen Inc.'s EPS (diluted) for fiscal 2025 was $14.23, up 88.2% from $7.56 in fiscal 2024. Over the twelve months to 30 June 2026 it was $16.09. Over the past ten years it has ranged from $2.69 (fiscal 2017) to $14.23 (fiscal 2025) — the current reading is the highest in ten years. Amgen Inc. ranks 2nd of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $14.23 | 88.23% |
| FY2024 | $7.56 | (39.47%) |
| FY2023 | $12.49 | 3.14% |
| FY2022 | $12.11 | 17.80% |
| FY2021 | $10.28 | (16.49%) |
| FY2020 | $12.31 | (4.43%) |
| FY2019 | $12.88 | 2.06% |
| FY2018 | $12.62 | 369.14% |
| FY2017 | $2.69 | (73.73%) |
| FY2016 | $10.24 | 13.02% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $4.37 | 30.84% |
| Mar 2026 | $3.34 | 36.33% |
| Dec 2025 | $2.45 | (58.68%) |
| Sep 2025 | $5.93 | 123.77% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. | $16.09 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| BMY Bristol Myers Squibb Company compare | $4.54 |
| NVO Novo Nordisk A/S compare | $4.09 |
| ABBV AbbVie Inc. compare | $3.54 |
| MRK Merck & Co., Inc. compare | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AMGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement